[go: up one dir, main page]

MX2009007284A - Cd200 y su receptor, cd200r, modulan la masa osea por medio de la diferenciacion de osteoclastos. - Google Patents

Cd200 y su receptor, cd200r, modulan la masa osea por medio de la diferenciacion de osteoclastos.

Info

Publication number
MX2009007284A
MX2009007284A MX2009007284A MX2009007284A MX2009007284A MX 2009007284 A MX2009007284 A MX 2009007284A MX 2009007284 A MX2009007284 A MX 2009007284A MX 2009007284 A MX2009007284 A MX 2009007284A MX 2009007284 A MX2009007284 A MX 2009007284A
Authority
MX
Mexico
Prior art keywords
cd200r
osteoclasts
differentiation
receptor
bone mass
Prior art date
Application number
MX2009007284A
Other languages
English (en)
Inventor
Agnes Vignery
Juan Zhang Ke
Li Jun
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2009007284A publication Critical patent/MX2009007284A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)

Abstract

Se describen métodos y composiciones relacionadas con CD200 y su receptor, CD200R que modula la masa ósea por medio de la diferenciación de los osteoclastos.
MX2009007284A 2007-01-11 2008-01-10 Cd200 y su receptor, cd200r, modulan la masa osea por medio de la diferenciacion de osteoclastos. MX2009007284A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88009407P 2007-01-11 2007-01-11
PCT/US2008/050708 WO2008089022A2 (en) 2007-01-11 2008-01-10 Cd200 and its receptor, cd200r, modulate bone mass via the differentiation of osteoclasts

Publications (1)

Publication Number Publication Date
MX2009007284A true MX2009007284A (es) 2009-10-08

Family

ID=39636627

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009007284A MX2009007284A (es) 2007-01-11 2008-01-10 Cd200 y su receptor, cd200r, modulan la masa osea por medio de la diferenciacion de osteoclastos.

Country Status (9)

Country Link
US (1) US20100104582A1 (es)
EP (1) EP2121015A4 (es)
JP (1) JP2010515751A (es)
KR (1) KR20090107056A (es)
CN (1) CN101687033A (es)
AU (1) AU2008206502A1 (es)
CA (1) CA2674578A1 (es)
MX (1) MX2009007284A (es)
WO (1) WO2008089022A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7408041B2 (en) 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
BRPI0707126A2 (pt) 2006-01-12 2011-04-19 Alexion Pharma Inc anticorpos para ox-2/cd200 e uso destes
CA2742610A1 (en) 2008-11-10 2010-05-14 Jun Li Compositions and methods for modulating cell-cell fusion via intermediate-conductance calcium-activated potassium channels
SG182408A1 (en) 2010-01-11 2012-08-30 Alexion Pharma Inc Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
WO2011100538A1 (en) 2010-02-11 2011-08-18 Alexion Pharmaceuticals, Inc. Therapeutic methods using an ti-cd200 antibodies
AR085141A1 (es) 2011-02-03 2013-09-11 Alexion Pharma Inc Un metodo para prolongar la supervivencia de un aloinjerto renal, uso de un anticuerpo anti-cd200 para prolongar la supervivencia de aloinjertos
CN102698266A (zh) * 2012-05-15 2012-10-03 中国医学科学院北京协和医院 Cd200在制备系统性红斑狼疮治疗药物中的应用
US10584342B2 (en) * 2014-03-21 2020-03-10 D5Pharma Inc. DNA aptamers specific to CD2000R1 and their therapeutic uses
GB201608197D0 (en) * 2016-05-10 2016-06-22 Ducentis Biotherapeutics Ltd Novel proteins
WO2019067499A1 (en) 2017-09-27 2019-04-04 Alexion Pharmaceuticals, Inc. BIOMARKER SIGNATURE FOR PREDICTING A TUMOR RESPONSE TO ANTI-CD200 THERAPY
US12139533B2 (en) 2017-12-20 2024-11-12 Alexion Pharmaceuticals, Inc. Liquid formulations of anti-CD200 antibodies
US11802154B2 (en) 2017-12-20 2023-10-31 Alexion Pharmaceuticals, Inc. Humanized anti-CD200 antibodies and uses thereof
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN113398270B (zh) * 2021-07-20 2023-04-25 中国科学院上海营养与健康研究所 一种治疗骨巨细胞瘤的方法
GB202115803D0 (en) 2021-11-03 2021-12-15 Ducentis Biotherapeutics Ltd Novel proteins
AU2023265174A1 (en) 2022-05-06 2024-12-12 Ducentis Biotherapeutics Limited Novel cd200 fusion proteins
CN119365483A (zh) 2022-05-06 2025-01-24 杜森蒂斯生物治疗有限公司 新型cd200融合蛋白
GB202306711D0 (en) 2023-05-05 2023-06-21 Ducentis Biotherapeutics Ltd Novel proteins

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020192215A1 (en) * 1999-04-13 2002-12-19 Schering Corporation, A New Jersey Corporation Novel uses of mammalian OX2 protein and related reagents
US20040198661A1 (en) * 2000-12-08 2004-10-07 Bowdish Katherine S. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US20060057651A1 (en) * 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
EP1482973B1 (en) * 2002-03-15 2009-08-19 Schering Corporation Methods of modulating cd200 receptors
WO2003103709A2 (en) * 2002-06-07 2003-12-18 Trillium Therapeutics Inc. Modulation of bone development
JP2007518827A (ja) * 2004-02-02 2007-07-12 シェーリング　コーポレイション Ｃｄ２００およびｃｄ２００ｒを調節する方法
BRPI0707126A2 (pt) * 2006-01-12 2011-04-19 Alexion Pharma Inc anticorpos para ox-2/cd200 e uso destes

Also Published As

Publication number Publication date
WO2008089022A2 (en) 2008-07-24
EP2121015A4 (en) 2010-03-24
US20100104582A1 (en) 2010-04-29
EP2121015A2 (en) 2009-11-25
JP2010515751A (ja) 2010-05-13
CN101687033A (zh) 2010-03-31
CA2674578A1 (en) 2008-07-24
AU2008206502A1 (en) 2008-07-24
KR20090107056A (ko) 2009-10-12
WO2008089022A3 (en) 2008-11-27

Similar Documents

Publication Publication Date Title
MX2009007284A (es) Cd200 y su receptor, cd200r, modulan la masa osea por medio de la diferenciacion de osteoclastos.
SG10201405377XA (en) Compositions and methods for antibodies targeting complement protein c5
IN2012DN02580A (es)
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
MX345909B (es) Anticuerpos anti-fgfr3 y métodos que los utilizan.
MX2009008918A (es) Activacion de celulas que presentan antigeno humano a traves de clec-6.
NO20083011L (no) Modulatorer av muskarine receptorer
MY173526A (en) Novel anti-?5?1 antibodies and uses thereof
TN2011000639A1 (en) Compounds which selectively modulate the cb2 receptor
MX2012006553A (es) Anticuerpos contra csf-1r humano y usos de los mismos.
CA2705357C (en) Formulations for taci-immunoglobulin fusion proteins
GT201300164A (es) Derivados de biciclo (3.2.1.) octilamida y sus usos
DE602007012072D1 (de) Orantagonisten
MX2020005214A (es) Formulaciones de anticuerpos.
MX2010005530A (es) Activadores de receptor de vitamina d nuevos y metodos de elaboracion de los mismos.
IL195341A0 (en) Methods and materials for making simvastatin and related compounds
TW201144300A (en) Tetrazole compounds which selectively modulate the CB2 receptor
NO20084006L (no) Modulatorer av muskarinreseptorer
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
IL191767A0 (en) Imidazoles as gaba-b receptor modulators
IN2012DN02876A (es)
WO2008021375A3 (en) Modulators of muscarinic receptors
MX2010000979A (es) Metodos y composiciones para tratar enfermedad autoinmune.
EP2129672A4 (en) ESTER AND CARBAMATE AZAADAMANTANE DERIVATIVES AND METHODS OF USE
TN2009000510A1 (en) Extended release formulation of nevirapine

Legal Events

Date Code Title Description
FG Grant or registration